2024
MRI after focal therapy for prostate cancer: what radiologists must know?
Jalilianhasanpour R, Arora S, Mansoori B, Raman S, Greenwood B, Sprenkle P, Schade G, Camacho M, Hosseini N, Westphalen A. MRI after focal therapy for prostate cancer: what radiologists must know? Abdominal Radiology 2024, 1-20. PMID: 39542951, DOI: 10.1007/s00261-024-04670-5.Peer-Reviewed Original Research
2023
PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER
Leapman M, Wang R, Long J, Sprenkle P, Ma X, Gross C. PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER. Journal Of Urology 2023, 209: e326. DOI: 10.1097/ju.0000000000003250.01.Peer-Reviewed Original Research
2020
PD38-05 CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL
Sprenkle* P, Carroll P, Probst S, Gorin M, Rowe S, Pienta K, Pouliot F, Patnaik A, Preston M, Alva A, Siegel B, Morris M. PD38-05 CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000917.05.Peer-Reviewed Original Research